Evidence map›Paper›PMID 25656896›Full record

ArticleCancer discovery2015

Blockade of specific NOTCH ligands: a new promising approach in cancer therapy.

Anaïs Briot, M Luisa Iruela-Arispe

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Host-DerivedFrontiers in cellular and infection microbiology · 2019
    Article
  13. Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies.Mediterranean journal of hematology and infectious diseases · 2019
    Review
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Anaïs BriotDepartment of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
M Luisa Iruela-ArispeDepartment of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, California. Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California. arispe@mcdb.ucla.edu.

Funding

Induction of Vascular MorphogenesisR01HL114086 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOUCHARD, LOUIS, IRUELA-ARISPE, M. LUISA · 2013 to 2016
$2.1M
NHLBI NIH HHS R01 HL114086
6 · The paper itself

Abstract

summaryThe signaling specificity conveyed by distinct combination of NOTCH receptors/ligands has remained elusive. In this issue of Cancer Discovery, through the development of ligand-specific NOTCH inhibitors, Kangsamaksin and colleagues uncovered unique signaling outcomes downstream of DLL- and JAG-receptor activation and demonstrated their effects in the suppression of tumor angiogenesis.

Indexed as

AnimalsFemaleHumansImmunoglobulin Fc FragmentsIntercellular Signaling Peptides and ProteinsNeoplasmsReceptor, Notch1Receptors, NotchRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsIntercellular Signaling Peptides and ProteinsReceptor, Notch1Receptors, NotchRecombinant Fusion Proteins

Identifiers

PMID25656896
PMCPMC4342039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.